全文获取类型
收费全文 | 1613篇 |
免费 | 73篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 36篇 |
妇产科学 | 16篇 |
基础医学 | 223篇 |
口腔科学 | 33篇 |
临床医学 | 141篇 |
内科学 | 300篇 |
皮肤病学 | 21篇 |
神经病学 | 159篇 |
特种医学 | 125篇 |
外科学 | 294篇 |
综合类 | 14篇 |
预防医学 | 63篇 |
眼科学 | 60篇 |
药学 | 79篇 |
中国医学 | 2篇 |
肿瘤学 | 96篇 |
出版年
2023年 | 20篇 |
2022年 | 37篇 |
2021年 | 44篇 |
2020年 | 27篇 |
2019年 | 26篇 |
2018年 | 51篇 |
2017年 | 31篇 |
2016年 | 46篇 |
2015年 | 38篇 |
2014年 | 55篇 |
2013年 | 91篇 |
2012年 | 104篇 |
2011年 | 106篇 |
2010年 | 56篇 |
2009年 | 48篇 |
2008年 | 105篇 |
2007年 | 112篇 |
2006年 | 83篇 |
2005年 | 101篇 |
2004年 | 82篇 |
2003年 | 86篇 |
2002年 | 76篇 |
2001年 | 16篇 |
2000年 | 14篇 |
1999年 | 11篇 |
1998年 | 12篇 |
1997年 | 10篇 |
1996年 | 9篇 |
1995年 | 8篇 |
1994年 | 6篇 |
1993年 | 7篇 |
1992年 | 6篇 |
1990年 | 8篇 |
1989年 | 5篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1978年 | 4篇 |
1975年 | 4篇 |
1974年 | 7篇 |
1933年 | 14篇 |
1931年 | 4篇 |
1930年 | 5篇 |
1913年 | 4篇 |
1912年 | 6篇 |
1911年 | 4篇 |
1884年 | 3篇 |
1883年 | 5篇 |
1881年 | 3篇 |
1880年 | 5篇 |
1879年 | 6篇 |
排序方式: 共有1690条查询结果,搜索用时 28 毫秒
31.
32.
Antibacterial resistance in Streptococcus pyogenes (GAS) from healthy carriers and tonsillitis patients and association with antibacterial sale in the Faroe Islands
下载免费PDF全文
![点击此处可从《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Marita D. Magnussen Shahin Gaini Hannes Gislason Karl G. Kristinsson 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2016,124(4):327-332
The aim of this study was to investigate the antibacterial resistance of Streptococcus pyogenes (GAS), and correlate the findings with the sales of erythromycin and tetracycline. General practitioners in the Faroe Islands were recruited to send oropharyngeal swabs. From an ongoing pneumococcal study, nasopharyngeal swabs were sampled from healthy children 0–7 years of age. Erythromycin susceptibility data from Iceland were obtained from the reference laboratory at the Landspitali University Hospital. Susceptibility testing in the Faroe Islands and Iceland was performed according to CLSI methods and criteria. The resistance rate to erythromycin and tetracycline found in patients in the Faroe Islands in 2009/2010 was 6% and 30% respectively. Tetracycline resistance in patients declined significantly from 2009 to 2010 (37–10%, p‐value = 0.006 < 0.05) and differed significantly between age groups (p‐value = 0.03 < 0.05). In Iceland, there was a peak in erythromycin resistance in 2008 (44%) and a substantial decrease in 2009 (5%). Although the prevalence of erythromycin and tetracycline resistance in the Faroe Islands and Iceland may be associated with antimicrobial use, sudden changes can occur with the introduction of new resistant clones. 相似文献
33.
34.
35.
36.
Kaufmann H Krömer E Nösslinger T Weltermann A Ackermann J Reisner R Bernhart M Drach J 《European journal of haematology》2003,71(3):179-183
OBJECTIVES: Deletion of chromosome 13q [del(13q)] has emerged as a major adverse prognostic factor in multiple myeloma (MM). Del(13q) is detected two to three times more frequently by interphase fluorescence in situ hybridization (FISH) than by metaphase cytogenetics (CG). However, it has remained unclear whether or not del(13q) detected by FISH only provides the same prognostic information as its detection by CG. METHODS: We investigated the outcome of 118 consecutive patients with newly diagnosed MM who were studied by both CG and FISH (RB-1 and/or D13S319 probes). RESULTS: CG revealed informative MM karyotypes in 35 patients (29.7%), with monosomy 13/del(13q) in 16 of them. FISH was indicative for a del(13q) in 43 patients (36.4%). A del(13q) by FISH was present in all 16 patients with monosomy 13/del(13q) by CG and also in four of 19 patients with informative karyotypes and diploid chromosome 13. Furthermore, del(13q) was present by FISH in 23 of 84 patients with diploid/non-informative metaphases by CG. Overall survival of patients with monosomy 13/del(13q) by CG and of patients with del(13q) by FISH only was not significantly different (median, 35.2 months vs. 33.2 months, P = 0.58). In contrast, patients with diploid chromosome 13 by either technique experienced prolonged survival (median, 65.6 months). Presence of abnormal karyotypes was significantly associated with an increased Ki67 growth fraction. CONCLUSION: FISH of chromosome 13q adds prognostic information to that provided by CG. It is suggested to use FISH analysis in clinical trials if risk stratifications take into consideration the chromosome 13q status. 相似文献
37.
The optimum therapy for patients with relapsed or refractory aggressive non-Hodgkin’s lymphomas (NHL) not qualifying for platinum-based
and/or high-dose chemotherapy is not known. We conducted a prospective phase II study evaluating a regimen consisting of gemcitabine
(1 g/m2, days 1 and 8), vinorelbine (30 mg/m2, days 1 and 8) and prednisone (100 mg/day, days 1–8) (GVP) given every 21 days. Fifteen patients with a median age of 68
years and a median of three previous therapies were enrolled. Diagnoses included B lymphoblastic (n=1), diffuse large B cell (n=10), anaplastic large T cell (n=2) and peripheral T-cell NHL (n=2). The median international prognostic index score was 3 (six patients with a score of 4 or 5). Five patients achieved a
complete remission and three patients a partial remission. The median overall survival was 13.8 months, and the median time
to next treatment was 4.4 months. Haematological toxicities of World Health Organisation grades 3/4 were leucopenia in 58%,
thrombocytopenia in 33% and anaemia in 17% of all courses. Three patients had grade 3 infections. There was no treatment-related
mortality. GVP shows substantial activity in poor prognosis relapsed or refractory aggressive lymphomas and is generally well
tolerated, but haematological toxicity is dose limiting. 相似文献
38.
Kröger N Einsele H Wolff D Casper J Freund M Derigs G Wandt H Schäfer-Eckart K Wittkowsky G Schmitz N Krüger W Zabelina T Renges H Ayuk F Krüll A Zander A;German Study-group Multiple Myeloma 《Bone marrow transplantation》2003,31(11):973-979
We investigated toxicity and efficacy of in vivo T-cell depletion with anti-thymocyte globulin (ATG) as part of an intensified myeloablative conditioning regimen followed by allogeneic stem cell transplantation in patients with advanced multiple myeloma. The conditioning regimen consisted of modified total body irradiation, busulfan and cyclophosphamide (n=15) or in the case of prior dose-limiting radiotherapy of busulfan and cyclophosphamide (n=3). The median age was 44 years (range, 29-53) and the median time from diagnosis to transplant was 12 months (range, 6-144). Grade II-IV acute graft-versus-host disease (GvHD) occurred in six patients (35%). Severe grade III/IV GvHD developed in one patient (6%). Three patients died of therapy-related causes (17%). A complete remission (CR) with negative immunofixation after allogeneic transplantation was seen in eight of the evaluable patients (53%). After a median follow-up of 41 months (range, 8-84), the estimated overall survival at 6 years for all patients is 77% (CI 95%: 58-96%). The estimated progression-free survival at 6 years for all patients is 31% (CI 95%: 2-59%) and 46% (CI 95%: 9-83%) for patients with CR. In vivo T-cell depletion with ATG resulted in a low rate of severe GvHD with low treatment-related mortality, and a substantial number of long-term survivors. 相似文献
39.
Michael R Tucker Jeremy Olivier Anna Pagel Hannes Bleuler Mohamed Bouri Olivier Lambercy José del R Millán Robert Riener Heike Vallery Roger Gassert 《Journal of neuroengineering and rehabilitation》2015,12(1)
Technological advancements have led to the development of numerous wearable robotic devices for the physical assistance and restoration of human locomotion. While many challenges remain with respect to the mechanical design of such devices, it is at least equally challenging and important to develop strategies to control them in concert with the intentions of the user.This work reviews the state-of-the-art techniques for controlling portable active lower limb prosthetic and orthotic (P/O) devices in the context of locomotive activities of daily living (ADL), and considers how these can be interfaced with the user’s sensory-motor control system. This review underscores the practical challenges and opportunities associated with P/O control, which can be used to accelerate future developments in this field. Furthermore, this work provides a classification scheme for the comparison of the various control strategies.As a novel contribution, a general framework for the control of portable gait-assistance devices is proposed. This framework accounts for the physical and informatic interactions between the controller, the user, the environment, and the mechanical device itself. Such a treatment of P/Os – not as independent devices, but as actors within an ecosystem – is suggested to be necessary to structure the next generation of intelligent and multifunctional controllers.Each element of the proposed framework is discussed with respect to the role that it plays in the assistance of locomotion, along with how its states can be sensed as inputs to the controller. The reviewed controllers are shown to fit within different levels of a hierarchical scheme, which loosely resembles the structure and functionality of the nominal human central nervous system (CNS). Active and passive safety mechanisms are considered to be central aspects underlying all of P/O design and control, and are shown to be critical for regulatory approval of such devices for real-world use.The works discussed herein provide evidence that, while we are getting ever closer, significant challenges still exist for the development of controllers for portable powered P/O devices that can seamlessly integrate with the user’s neuromusculoskeletal system and are practical for use in locomotive ADL. 相似文献
40.
Erwin?Stolz Franziska?Gro?sch?dl Hannes?Mayerl éva?Rásky Wolfgang?FreidlEmail author 《BMC medical ethics》2015,16(1):81